Elephas

About Elephas

Elephas is a life sciences company operating in the oncology diagnostics market, focused on developing a platform to predict patient response to immunotherapy. Founded in April 2020 by Maneesh Arora, the company was inspired by the paradox that elephants, despite their large size, rarely get cancer. Arora, with a two-decade-long career in cancer diagnostics, including a ten-year tenure as COO at Exact Sciences and experience at Third Wave Technologies, established Elephas to address the critical challenge of matching cancer patients with effective treatments.

The company's core business revolves around a proprietary diagnostic platform that assesses how live tumor fragments respond to various cancer therapies outside of the body (*ex vivo*). This approach is a departure from traditional methods that rely on fixed, dead tissue. The platform uses fresh patient biopsies, keeping the cells alive and preserving the native tumor microenvironment—the complex ecosystem of tumor cells, immune cells, and stroma. To achieve this, Elephas developed proprietary technologies, including the Elephas Live Edge™ instrument for precisely cutting tissue and Elephas Live Protect™, a specialized hydrogel that encapsulates and maintains the viability of the tumor fragments.

By treating these live samples with potential immunotherapies, the platform utilizes advanced multimodal microscopy and metabolic imaging to visualize immune cell activity, such as T-cell activation and cancer cell killing, in real-time. The goal is to provide predictive data on treatment efficacy within 72 hours of a biopsy, empowering clinicians to make more informed decisions before a patient begins a lengthy and costly course of therapy. The platform is designed to be tumor-agnostic, applicable across various cancer types and immunotherapies. The primary clients are biopharmaceutical companies and clinicians. For biopharma partners, the platform offers a service to accelerate the development of new immunotherapy drugs, a service officially launched in 2023. For clinicians, the platform aims to be a decision support tool to personalize cancer treatment.

Elephas has achieved significant financial milestones, securing $116.5 million in total funding as of its Series C round in January 2024. This includes an initial $8 million from the founder and seed investors, a $41.5 million Series B in 2022, and a $55 million Series C. The company is actively engaged in observational clinical trials to correlate its platform's predictions with actual patient outcomes and announced a collaboration with Mayo Clinic in early 2024 to advance these studies.